| 1.81 0.074 (4.29%) | 02-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.16 | 1-year : | 2.52 |
| Resists | First : | 1.85 | Second : | 2.16 |
| Pivot price | 1.71 |
|||
| Supports | First : | 1.65 | Second : | 1.52 |
| MAs | MA(5) : | 1.76 |
MA(20) : | 1.69 |
| MA(100) : | 1.95 |
MA(250) : | 2.3 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 71.6 |
D(3) : | 64.2 |
| RSI | RSI(14): 61.9 |
|||
| 52-week | High : | 3.79 | Low : | 1.5 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NSPR ] has closed above the upper band by 0.6%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 22.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.85 - 1.86 | 1.86 - 1.87 |
| Low: | 1.79 - 1.8 | 1.8 - 1.81 |
| Close: | 1.84 - 1.85 | 1.85 - 1.86 |
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.
Sat, 21 Feb 2026
Aberdeen Group plc Makes New Investment in InspireMD, Inc. $NSPR - MarketBeat
Wed, 04 Feb 2026
This Insider Has Just Sold Shares In InspireMD - Sahm
Mon, 02 Feb 2026
InspireMD CCO Gleason sells $99k in NSPR stock - Investing.com
Fri, 30 Jan 2026
InspireMD (NYSE:NSPR) Stock Price Down 1.8% - Should You Sell? - MarketBeat
Sat, 10 Jan 2026
InspireMD (NASDAQ:NSPR) shareholders have endured a 81% loss from investing in the stock five years ago - Yahoo Finance
Thu, 27 Nov 2025
Is InspireMD (NASDAQ:NSPR) In A Good Position To Invest In Growth? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 42 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 23 (%) |
| Held by Institutions | 54.6 (%) |
| Shares Short | 30 (K) |
| Shares Short P.Month | 66 (K) |
| EPS | -0.81 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.52 |
| Profit Margin | 0 % |
| Operating Margin | -517.3 % |
| Return on Assets (ttm) | -45.5 % |
| Return on Equity (ttm) | -87.7 % |
| Qtrly Rev. Growth | 39.4 % |
| Gross Profit (p.s.) | 0.04 |
| Sales Per Share | 0.18 |
| EBITDA (p.s.) | -1.1 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -2.32 |
| PEG Ratio | 0 |
| Price to Book value | 1.2 |
| Price to Sales | 10.07 |
| Price to Cash Flow | -2.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|